权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Epigenetic gene repression in pulmonary fibrosis

肺纤维化中的表观遗传基因抑制

基本信息

批准号：
10432006
负责人：
Giovanni Ligresti
金额：
$ 41.25万
依托单位：
BOSTON UNIVERSITY MEDICAL CAMPUS
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-07-01 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10432006
关键词：
Address Architecture Attention Attenuated Binding Bleomycin CREB1 gene Cells Chronic Cicatrix Connective Tissue Coupled Data Deposition Development Disease Disease Progression Epigenetic Process Fibroblasts Fibrosis G9a histone methyltransferase Gene Activation Gene Deletion Gene Expression Genes Genetic Transcription Histones Human In Vitro Inflammation Injury Intervention Investigation Label Lung Lung diseases Lung fibrogenesis Lysine Maintenance Mediating Mediator of activation protein Metabolic Methylation Methyltransferase Mitochondria Modeling Modification Mus Myofibroblast Normal tissue morphology Nucleic Acid Regulatory Sequences Organ failure Pathologic Pathologic Processes Pathway interactions Phase Process Promoter Regions Pulmonary Fibrosis RNA Interference RNA interference screen Reader Repression Resolution Role Stimulus Testing Therapeutic Therapeutic Intervention Time Tissues Transcription Repressor Transcriptional Regulation Uncertainty deep sequencing epigenetic regulation experimental study fibrogenesis fibrotic lung gene repression genetic approach genome-wide human disease idiopathic pulmonary fibrosis in vivo indium-bleomycin inhibitor insight knock-down loss of function lung injury mitochondrial dysfunction mitochondrial metabolism mortality mouse genetics mouse model novel overexpression programs research study small molecule targeted treatment tissue repair

项目摘要

PROJECT SUMMARY Pulmonary fibrosis represents an increasing cause of mortality worldwide and despite decades of investigation, considerable uncertainty exists as how this disease initiates and progresses. While multiple fibrogenic molecules have been found to drive aberrant matrix deposition, the mechanisms responsible for maintaining persistent and self-sustaining fibrogenesis are largely unknown. Targeting mechanisms that perpetuate the pathological state of fibroblasts during disease progression may serve as an attractive therapeutic strategy to halt lung fibrosis. The current proposal addresses the role of epigenetic gene repression in regulating fibroblast activation and lung fibrosis development. We will investigate the role of histone 3 lysine 9 methylation (H3K9me) as an important epigenetic modification that represses the transcription of genes essential to maintaining or returning lung fibroblasts to an anti-fibrotic or quiescent inactive state. Our preliminary data demonstrate that inhibition of H3K9 methylation by targeting the H3K9 methyltransferase G9a or the epigenetic reader CBX5 potently inhibits fibroblast activation by fibrogenic stimuli. Mechanistically, our data demonstrate that both G9a and CBX5 are directly involved in repressing PGC1, a master regulator of mitochondria metabolism significantly downregulated in diseased lung fibroblasts. Loss of PGC1 expression promotes fibroblast activation, while restoring PGC1 via epigenetic mechanisms reverses fibroblast activation. We will use loss of function strategies to target the epigenetic regulators CBX5 and G9a to investigate their mechanistic roles in switching fibroblasts between activated and quiescence states. Using mouse genetics approaches we will investigate the benefits of inhibiting H3K9 methylation in halting disease progression in bleomycin-induced lung fibrosis models. As our preliminary data strongly support an anti-fibrotic function for PGC1 during lung fibroblast activation in vitro, in this proposal we will further characterize its anti-fibrotic function and evaluate upstream and downstream transcriptional network that mediate its anti-fibrotic functions. Taken together, the proposed research studies will reveal critical epigenetic targets for therapeutic interventions aimed at halting or reversing the progression of pulmonary fibrosis.

项目摘要肺纤维化代表了全世界死亡率增加的原因，尽管经过几十年的研究，这种疾病如何发生和发展存在相当大的不确定性。虽然多发性纤维化分子已被发现驱动异常基质沉积，负责维持基质沉积的机制。持续的和自我维持的纤维形成在很大程度上是未知的。目标锁定机制，疾病进展过程中成纤维细胞的病理状态可以作为一种有吸引力的治疗策略，阻止肺纤维化。目前的建议解决的作用，表观遗传基因的抑制，调节成纤维细胞活化和肺纤维化发展。我们将研究组蛋白3赖氨酸9甲基化的作用（H3K9me）作为一种重要的表观遗传修饰，其抑制对以下关键基因的转录：维持或使肺成纤维细胞恢复到抗纤维化或静止的非活性状态。我们的初步数据证明通过靶向H3K9甲基转移酶G9a或表观遗传修饰抑制H3K9甲基化， reader CBX5有效抑制纤维化刺激引起的成纤维细胞活化。我们的数据表明， G9a和CBX5都直接参与抑制PGC1 β，PGC1 β是线粒体的主要调节因子，在患病的肺成纤维细胞中代谢显著下调。PGC1 β表达的缺失促进成纤维细胞活化，而通过表观遗传机制恢复PGC1 β逆转成纤维细胞活化。我们将使用功能丧失策略来靶向表观遗传调节因子CBX5和G9a，以研究它们的功能。在活化和静止状态之间转换成纤维细胞的机械作用。利用老鼠遗传学我们将研究抑制H3K9甲基化在阻止疾病进展中的益处，博莱霉素诱导的肺纤维化模型。由于我们的初步数据强烈支持抗纤维化功能， PGC1在体外肺成纤维细胞活化过程中起重要作用，在本研究中，我们将进一步研究其抗纤维化作用。功能，并评估介导其抗纤维化功能的上游和下游转录网络。综上所述，拟议的研究将揭示关键的表观遗传靶点，旨在阻止或逆转肺纤维化进展的干预措施。

项目成果

期刊论文数量（6）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Wet-dry-wet drug screen leads to the synthesis of TS1, a novel compound reversing lung fibrosis through inhibition of myofibroblast differentiation.

DOI：
10.1038/s41419-021-04439-4
发表时间：
2021-12-17
期刊：
Cell death & disease
影响因子：
9
作者：
Ring NAR;Volpe MC;Stepišnik T;Mamolo MG;Panov P;Kocev D;Vodret S;Fortuna S;Calabretti A;Rehman M;Colliva A;Marchesan P;Camparini L;Marcuzzo T;Bussani R;Scarabellotto S;Confalonieri M;Pham TX;Ligresti G;Caporarello N;Loffredo FS;Zampieri D;Džeroski S;Zacchigna S
通讯作者：
Zacchigna S

Kidney endothelial cell heterogeneity, angiocrine activity and paracrine regulatory mechanisms.

肾内皮细胞异质性、血管分泌活性和旁分泌调节机制。